Cure Parkinson’s iLCT Pipeline Research Acceleration Programme opens new funding call
Cure Parkinson’s is excited to announce the opening of the iLCT Pipeline Research Acceleration Programme for February 2026. We are welcoming applications to investigate secukinumab in an alpha-synuclein model of Parkinson’s. What is the iLCT Pipeline Research Acceleration Programme? Each year, a committee of over…
Cure Parkinson’s welcomes new research committee members and interns
The research committee are an independent group of 16-20 Parkinson’s researchers, clinicians, industry representatives, and people with Parkinson’s that review and assess all our incoming grant funding applications. In 2026, we are excited to welcome several new members and interns to this committee. Who are…
Impact report highlights research into finding a cure for Parkinson’s
Cure Parkinson’s are proud to publish their latest impact report today. The charity’s achievements range from convening researchers and industry partners to initiating strategic partnerships and from delivering webinars to being the largest not for profit funder of the largest clinical trial for Parkinson’s in…
Cure Parkinsons and Van Andel Institute renew funding for Parkinson’s clinical trial programme
Cure Parkinson’s and Van Andel Institute (VAI) have renewed a funding agreement to support the International Linked Clinical Trials (iLCT) programme, the world’s largest drug repurposing clinical trial initiative for Parkinson’s disease. As part of the three-year agreement, VAI and Cure Parkinson’s each pledge $750,000…
Launch of a Global Alliance for Parkinson’s Platforms (GAPP); bringing together international leaders of Parkinson’s platform trials
Stakeholders involved in the setup and running of Parkinson’s platform trials met in November for the second annual International PD-Platform Meeting. The result was the launch of GAPP with representatives from the UK, France, the US, Norway, and Australia. GAPP is facilitated by a collaboration…